Behar A, Nathan P, Lavieuville M, Allaert F A
Service de Biophysique et Médecine Nucléaire, Hôtel-Dieu, Paris, France.
Phlebologie. 1993 Oct-Dec;46(4):721-31.
The purpose of this trial was to evaluate the clinical effect of Veinotonyl 75 in 42 women, 42 +/- 11 years old, with orthostatic cyclic edema. The main evaluation criterion was the result of a capillary filtration test with 99 mTc albumin which was performed at day 0 and at day 30 after treatment. At day 0, all the women had abnormal results ie an albumin retention > or = 8% (mean: 14.3% +/- 4.8%). At day 30, 75% of the patients were normalized in the Veinotonyl 75 group versus 38% in the placebo group (p < 0.02). The albumin retention in Veinotonyl 75 group was under the pathological level (mean: 5.2% +/- 4.8%) while it was over in the placebo group (mean: 9.4% +/- 7%). This study confirms the activity of Veinotonyl 75 on capillar protein hyperfiltration and on return venous circulation.
本试验的目的是评估Veinotonyl 75对42名年龄在42±11岁、患有体位性周期性水肿的女性的临床疗效。主要评估标准是在治疗第0天和第30天进行的用99mTc白蛋白进行的毛细血管滤过试验结果。在第0天，所有女性的结果均异常，即白蛋白潴留≥8%（平均：14.3%±4.8%）。在第30天，Veinotonyl 75组75%的患者恢复正常，而安慰剂组为38%（p<0.02）。Veinotonyl 75组的白蛋白潴留处于病理水平以下（平均：5.2%±4.8%），而安慰剂组则高于此水平（平均：9.4%±7%）。本研究证实了Veinotonyl 75对毛细血管蛋白超滤和静脉回流的作用。
